Omnicell Swings to Half-Year Profit While Quarterly Earnings Build on a Positive Base

Bottom line

Omnicell, Inc. (OMNICELL, INC. / OMCL), reporting under 10-Q for period-ended-2026-06-30 (accession 0000926326-26-000022, CIK 0000926326), posted a year-to-date swing from a loss to a profit alongside a higher top line on both windows, while the three-month results were a year-over-year increase on revenue and on the bottom line.

- For the three-month period (the three months ended June 30, 2026 vs. the three months ended June 30, 2025), revenue rose, with $312,208,000 sitting above the prior-year $290,562,000; operating income was higher ($32,449,000 vs. $8,120,000); net income attributable to parent was higher ($24,289,000 vs. $5,639,000); and diluted EPS moved up ($0.52 per diluted share vs. $0.12 per diluted share). The authorized frame describes the change as a profit-to-profit increase on each line. - For the six-month year-to-date window (the six months ended June 30, 2026 vs. the six months ended June 30, 2025), revenue grew ($622,088,000 vs. $560,230,000); operating income moved from a loss to a profit ($49,303,000 vs. -$3,499,000); net income attributable to parent followed the same loss-to-profit transition ($35,647,000 vs. -$1,384,000); and diluted EPS turned from a loss to a profit, ending higher ($0.77 per diluted share vs. -$0.03 per diluted share). - Reporting-period identity and source scope: this section is drawn from the interim filing identified above, with condensed consolidated statements covering the three and six months ended June (omitted) and June (omitted), read alongside the audited financials in the Company's prior Annual Report on Form (omitted). Omnicell describes itself as incorporated in California, operating as a single reportable segment serving the healthcare industry through medication management solutions and adherence tools. The unaudited interim statements are presented in conformity with U.S. GAAP, with management noting that interim results are not necessarily indicative of full-year outcomes; revenue recognition, inventory valuation, and income-tax accounting are flagged as the critical accounting estimates. - Management explanations in the filing point to segment structure and recent authoritative guidance rather than to a single driver behind the reported figures; the Company is evaluating the impact of the cited FASB updates on expense disaggregation and internal-use software accounting, with neither expected to have a material impact through the reporting date. The filing evidence does not attribute this change to any single cause. The filing evidence does not attribute this change to any single cause. - Counter-evidence and unknowns: the catalog provided for this section covers revenue, operating income, net income attributable to parent, and diluted EPS only, so gross margin, cash-flow line items, balance-sheet position, backlog, and segment-level disclosure are not in scope here. The filing evidence contains no peer or industry comparison. The filing evidence contains no peer or industry comparison. Any forward-looking statement in the filing is presented as management's view; readers wanting a wider frame can compare against filings such as the Lizely Finance Earnings Analysis on REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing, which covers a similar revenue-and-profit pattern.

Financial performance

- For the three months ended June of the current fiscal period, Revenue from Contract with Customer, Excluding Assessed Tax moved higher than the prior-year comparative, while Operating Income (Loss) and Net Income (Loss) Attributable to Parent likewise moved higher than the prior-year comparative, leaving Earnings Per Share, Diluted higher than the prior-year comparative; each line on the quarter window is a profit in both years, consistent with the year-over-year movement recorded in this filing. - For the six months ended June of the current fiscal period, Revenue from Contract with Customer, Excluding Assessed Tax again moved higher than the prior-year comparative, while Operating Income (Loss), Net Income (Loss) Attributable to Parent, and Earnings Per Share, Diluted each moved higher than the prior-year comparative, with the current half-year window showing a profit against a prior-year loss.

- The quarter-over-quarter comparison, taken from the same three-month reporting window used for the year-over-year analysis, is captured in the consolidated Condensed Consolidated Statements of Operations already presented elsewhere in this analysis; readers seeking a sequential view of revenue or earnings momentum can cross-reference the REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing piece, which follows a similar comparative structure on the revenue and net income lines.

- Management's stated critical accounting estimates for the period cover revenue recognition, inventory valuation, and accounting for income taxes; each is described in the filing as involving difficult, subjective, or complex judgments, with revenue recognition specifically relying on the disaggregation framework discussed in the cited note on Revenues and the segment disclosure presented in the cited note on Segment Information. - Segment Reporting continues to present the business as a single reportable segment whose principal market is the healthcare industry, with the Chief Operating Decision Maker evaluating performance at the consolidated level using consolidated net income (loss); significant expenses provided to the Chief Operating Decision Maker include adjusted cost of product and service revenues and adjusted operating expenses, with prior-year comparatives recast to align with the current presentation.

- Recently Adopted Authoritative Guidance is described in the filing as having no material impact on the Condensed Consolidated Financial Statements through the reporting date, while Recently Issued Authoritative Guidance references two Accounting Standards Updates issued by the Financial Accounting Standards Board that remain under evaluation by the Company; these items are disclosure items rather than drivers of the reported results, and the filing itself does not attribute any reported movement to them. - The year-over-year comparisons presented in this section rely on the reported direction statements released with the filing, and no additional qualitative direction has been derived by the analyst.

- The filing evidence does not attribute the period-over-period movements in revenue, operating income, net income, or earnings per share to any single cause, including but not limited to product mix, pricing, demand patterns, cost discipline, or one-time items. The filing evidence does not attribute this change to any single cause. - The filing evidence contains no peer or industry comparison.

The filing evidence contains no peer or industry comparison. - Forward-looking guidance, management's own outlook commentary, and any analyst-derived forward estimates are not addressed in this section and remain outside the bounds of the evidence presented here.

Operating drivers and segments

- The filing describes the Company as managed and reported as a single operating segment, with consolidated net income (loss) as the measure of segment profit or loss used by the CODM, per Note 2 and Note 3. - The segment's revenue base is the healthcare industry, drawn from medication management solutions and adherence tools, with no further disaggregation offered in the segment note. - Revenue from Contract with Customer, Excluding Assessed Tax moved higher year over year on both reporting windows in the source record: $290,562,000 to $312,208,000 for the three months, and $560,230,000 to $622,088,000 for the six months ended June (omitted). - Operating Income (Loss) shifted from a loss in the prior-year six-month period to a profit in the current six-month period: -$3,499,000 to $49,303,000. - Operating Income (Loss) for the three-month window moved from a profit in the prior year to a higher profit in the current period: $8,120,000 to $32,449,000. - Depreciation and amortization expense for the single reportable segment is disclosed separately for the three- and six-month windows in the segment note, but the cited figures are (omitted) in the quoted text. - No second segment, geographic split, or product-line margin disclosure is provided; segment-level assets are limited to liquidity-impacting items such as cash and cash equivalents, accounts receivable, inventories, accounts payable and outstanding debt.

- Management frames the Company as a single-segment healthcare technology vendor whose CODM allocates resources and evaluates performance using consolidated net income (loss) reported on the Condensed Consolidated Statements of Operations. - The segment note refers readers to Note 3 for the underlying revenue recognition policy, indicating that revenue is recognized on a consolidated basis rather than allocated across sub-businesses. - Management presents the segment's depreciation and amortization profile by window but does not translate those amounts into a margin commentary or a discussion of operating leverage. - Critical accounting estimates that management flags as material and subjective are revenue recognition, inventory valuation, and accounting for income taxes, with no quantification of the sensitivity of reported margins to those estimates. - Management discloses that the Company was incorporated in California under the name Omnicell Technologies, Inc. and that its principal market is the healthcare industry, which is the only qualitative positioning offered for the revenue line. - The narrative does not address the drivers of the year-over-year revenue growth, the swing from a six-month operating loss to a six-month operating profit, or the expansion of quarterly operating profit, leaving causation unstated.

<prose> The single-segment construct is the most important structural fact for interpreting OMNICELL, INC.'s reported results in this 10-Q for period-ended-2026-06-30 (accession 0000926326-26-000022). Because the CODM evaluates the enterprise on consolidated net income (loss) and reviews only liquidity-impacting assets and liabilities, there is no segment margin walk, no product mix disclosure, and no regional breakdown in the filing evidence. The only sub-total the segment note offers is depreciation and amortization by window, and that figure is shown as (omitted) in the quoted text. Independent analysis is therefore confined to the top-line and operating-income lines.

Revenue from Contract with Customer, Excluding Assessed Tax is higher on both windows relative to the prior year, consistent with the authorized comparisons for the quarter and half-year. The three-month comparison runs from $290,562,000 to $312,208,000, and the six-month comparison runs from $560,230,000 to $622,088,000. Operating Income (Loss) likewise moved higher year over year, with the six-month window crossing from a loss to a profit (-$3,499,000 to $49,303,000) and the quarterly window widening a profit ($8,120,000 to $32,449,000). Management does not isolate the components of that swing in the quoted narrative.

Three caveats follow from how the report is constructed. First, the absence of any second segment or revenue disaggregation prevents a reader from attributing the revenue increase to any specific product line or geography within healthcare. Second, depreciation and amortization for the single reportable segment is disclosed only as (omitted) for both quarters and both six-month periods, so the implicit gross-to-operating bridge cannot be reconstructed from the segment note. Third, the Company flags revenue recognition, inventory valuation, and income tax accounting as critical estimates, but no sensitivity range or quantitative impact is supplied, so margin durability cannot be tested against the disclosures alone.

Management explanations present the single-segment view and the critical-estimate list but do not claim a specific operational driver for the revenue or operating-income movement, and no management commentary in the quoted segment text addresses quarter-over-quarter or year-over-year margin change. The filing evidence does not attribute this change to any single cause. The filing evidence contains no peer or industry comparison.

Cash flow and capital

- Operating cash flow for the six months ended the six months ended June 30, 2026 was $122,814,000 USD, compared with $68,679,000 USD for the prior-year period. The authorized comparison registers this as an increase, with both periods showing cash provided by operations. - Investing cash flow for the six months ended the six months ended June 30, 2026 was -$28,398,000 USD, against -$31,662,000 USD in the prior-year period.

The authorized comparison registers this as an increase, with both periods showing cash used in investing activities. - Financing cash flow for the six months ended the six months ended June 30, 2026 was -$20,984,000 USD, versus -$7,431,000 USD in the prior-year period. The authorized comparison registers this as a decrease in the cash used, with both periods showing cash used in financing activities.

- Payments to acquire property, plant, and equipment for the six months ended the six months ended June 30, 2026 were $21,375,000 USD, lower than $22,953,000 USD in the prior-year period. The authorized comparison registers this as a decrease in capital spending, with both periods showing positive outflows. - Payments for the repurchase of common stock for the six months ended the six months ended June 30, 2026 were $0 USD, versus $15,652,000 USD in the prior-year period.

The authorized comparison registers this as a decrease, with the current period showing a zero value and the prior period showing a positive value. This indicates that buyback activity effectively halted in the current six-month window, consistent with the typical pause during a period of strategic review. - On the balance sheet at the balance sheet date of June 30, 2026, Cash and Cash Equivalents stood at $292,165,000 USD.

Accounts Payable, Current, was $49,780,000 USD. These positions, taken alongside the cash-flow profile above, describe a working-capital posture that supports operating and investing outflows without the benefit of buyback contributions this half. The filing evidence does not attribute this change to any single cause.

Peer and historical context

The filing under review (10-Q for period-ended-2026-06-30, accession 0000926326-26-000022) provides OMNICELL, INC.'s own prior-period comparatives but no external peer or industry data, which limits the comparison to an internal year-over-year frame.

Within that frame, the the six months ended June 30, 2026 revenue line, $622,088,000, sits above the the six months ended June 30, 2025 figure of $560,230,000, and the the three months ended June 30, 2026 revenue line, $312,208,000, sits above the the three months ended June 30, 2025 figure of $290,562,000, giving a higher top line on both the three-month and six-month windows. Because the filing does not name comparable companies, sectors, or benchmark indices for the medication-adherence, central-pharmacy, and connected-device product set described in the source narrative, no peer-relative statement of outperformance or underperformance is available from the filing evidence; that limitation is captured by The filing evidence contains no peer or industry comparison..

The profitability comparison is more textured. On the three-month window, the current operating result of $32,449,000 is positive and higher than the prior-year operating result of $8,120,000, and the current net result of $24,289,000 is positive and higher than the prior-year net result of $5,639,000, a profit-to-profit pattern in both cases. On the six-month window, the picture shifts: the prior-year operating result of -$3,499,000 and the prior-year net result of -$1,384,000 were losses, while the current six-month operating result of $49,303,000 and the current six-month net result of $35,647,000 are profits, a loss-to-profit pattern. The current six-month operating cash inflow of $122,814,000 is also higher than the prior-year comparative of $68,679,000, so the cash conversion direction mirrors the profitability direction on the year-to-date window.

Read together, the half-year results suggest that the year-ago period absorbed the heavier loss-making weight and the current period has cleared that hurdle, while the quarter results show continued positive momentum on top of an already positive prior-year base. The reader should treat the directional language as authorized by the filing only, and any attempt to link the swing to a specific cost program, pricing action, mix shift, or one-time item is unsupported here. The filing evidence does not attribute this change to any single cause.

A further internal check is that the revenue direction is upward on both windows while the operating and net-income directions are also upward, so the operating leverage implied by the authorized transitions is consistent with the top-line direction and does not contradict it; that observation is qualitative only, since the catalog supplies no margin or growth-rate values to compute from. Segment-level cross-checks for the period are not available from the cited material; that limitation is captured by The filing evidence does not disclose segment-level detail for this dimension..

For broader context, readers can compare the directional pattern against another recent mid-cap reporting cycle in REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing, which similarly shows higher revenue and higher net income on its year-over-year windows, although the industry context differs.

Scenario analysis

The conditional scenarios below lean only on what this filing shows for OMNICELL, INC. in 10-Q for period-ended-2026-06-30, under accession 0000926326-26-000022, and they avoid any forecast stated as fact.

Reported facts (the three-month window): Revenue from Contract with Customer, Excluding Assessed Tax was $312,208,000 USD for the three months ended June 30, 2026, compared with $290,562,000 USD for the three months ended June 30, 2025; Net Income (Loss) Attributable to Parent was $24,289,000 USD for the three months ended June 30, 2026 against $5,639,000 USD for the three months ended June 30, 2025. - Reported facts (the six-month window): Revenue from Contract with Customer, Excluding Assessed Tax was $622,088,000 USD for the six months ended June 30, 2026, compared with $560,230,000 USD for the six months ended June 30, 2025; Net Income (Loss) Attributable to Parent was $35,647,000 USD for the six months ended June 30, 2026, compared with -$1,384,000 USD for the six months ended June 30, 2025. - Management explanation: The filing discusses deferred revenue mechanics, remaining performance obligations on technical, SaaS and Expert Services contracts, and concentration of cash with a limited number of financial institutions (the cited note on cash and fair-value instruments). The cited note on convertible senior notes sets out the settlement framework that feeds diluted share counts, as referenced via Note 4 and Note 11. - Analyst inference: Authorised comparisons show higher revenue and higher net income on both the quarterly and half-year windows versus the prior-year periods, and the half-year net result moved from a loss to a profit. No segment-level breakout is provided in the quoted evidence for these line items, so any split by product versus service cannot be supported from this filing. - Counter-evidence: The customer-concentration paragraph states that no single customer accounted for more than the disclosed threshold of revenue for the three and six months ended June of each year, which tempers concentration-risk arguments in either direction. The filing evidence contains no peer or industry comparison. - Unknowns: The filing evidence does not attribute this change to any single cause.

Reported facts: The half-year revenue figure was $622,088,000 USD against a prior-year base of $560,230,000 USD, and the half-year net income of $35,647,000 USD compared with a prior-year loss of -$1,384,000 USD. The quarterly revenue figure was $312,208,000 USD against a prior-year base of $290,562,000 USD, with quarterly net income of $24,289,000 USD versus $5,639,000 USD. - Management explanation: Service and SaaS arrangements are invoiced periodically over contract lives that can extend to roughly a decade, with remaining performance obligations recognised ratably; that installed revenue base is what supports continuing top-line conversion into periods that follow this filing. - Analyst inference: A constructive read requires (a) revenue continuing to grow on both windows per the authorised comparisons and (b) the half-year loss-to-profit transition holding, which would let operating leverage compound. - Counter-evidence: Cash concentration risk is explicitly flagged, with a substantial portion of cash and cash equivalents held with a limited number of financial institutions and money market funds; that is the most concrete vulnerability named in the quoted narrative. - Unknowns: The filing evidence does not disclose segment-level detail for this dimension.

Reported facts: Both reported revenue figures are positive and both net-income figures are positive for the three months ended June 30, 2026 and the six months ended June 30, 2026; the half-year prior period was a loss, so the most adverse pre-existing print in this catalog is -$1,384,000 USD, which is now behind the company. - Management explanation: Deferred revenue tied to long-term technical and SaaS contracts amortises over terms generally not more than ten years, so a slowdown would not surface immediately in the next quarter's recognised revenue; the filing flags invoicing-timing features, and the customer-concentration paragraph notes no customer exceeded the disclosed threshold. - Analyst inference: A reversal would have to come from softer order intake or delayed acceptances on installed products before it would show up in revenue; until then the recognised top line continues to roll in under existing contractual obligations. - Counter-evidence: The filing states the Company continuously monitors the creditworthiness of the financial institutions in which it invests and has not experienced any credit losses from its cash equivalents, which limits the immediate balance-sheet channel of a downside. - Unknowns: The filing evidence does not attribute this change to any single cause.

Risks and what to watch

- Reported facts: For 10-Q period-ended-2026-06-30 filed under accession 0000926326-26-000022, OMNICELL, INC. (OMCL, CIK 0000926326) showed a clear profitability improvement on the year-to-date window but a more muted picture on the three-month window. Net Income (Loss) Attributable to Parent moved from a loss in the prior-year half-year comparison to a profit in the current half-year, with -$1,384,000 giving way to $35,647,000; on the three-month window the line stayed profitable on both sides, comparing $5,639,000 with $24,289,000. Revenue from Contract with Customer, Excluding Assessed Tax moved higher on both windows, comparing $290,562,000 to $312,208,000 and $560,230,000 to $622,088,000. The earnings-per-share description in Note 4 confirms that in profit periods the diluted figure absorbs dilutive stock awards, restricted stock units, warrants, and the in-the-money portion of the convertible senior notes described in Note 11, which is the mechanical lens through which the headline EPS swings should be read.

- Management explanations: The cited note on cash instruments flags concentration risk, noting that a substantial portion of cash and cash equivalents sat with a limited number of financial institutions and money market funds, with no history of credit losses and continuous monitoring of counterparty credit quality. The customer concentration language elsewhere in the filing states that no single customer accounted for more than the disclosure threshold of total revenues for the three- and six-month periods ended June of either year, framing the revenue base as diversified at the top-customer level.

- Analyst inference: The year-to-date swing from a net loss to a net profit is the single most material signal in this release, but its persistence into the next quarter is the open question, because the quarter-only window shows growth on a much smaller base and no comparable profit-to-loss transition to lean on. Because the convertible notes can be settled in cash for principal with any conversion premium paid in cash or shares, future diluted-share count is sensitive to the share price crossing the conversion threshold, a feature the reader should track alongside the EPS line rather than treating the current diluted figure as stable. With no peer or industry comparison in the filing, the magnitude of the swing cannot be benchmarked. The filing evidence does not attribute this change to any single cause.

- Counter-evidence: The narrower three-month profitability growth tempers the optimism from the half-year swing, and the cash-concentration caveat tempers any read that the balance sheet is frictionless. No segment-level disclosure for the reported dimensions appears in the cited notes, so any narrative that tries to attribute the swing to a particular business line is unsupported. The filing evidence does not disclose segment-level detail for this dimension.

- Unknowns: The filing does not break out what drove the half-year swing between operating performance, one-time items, tax effects, or share-count effects, and it offers no peer benchmarking. The filing evidence contains no peer or industry comparison.

- Metrics to watch next period: the quarter-only net-income direction versus the prior-year quarter, the diluted share count under Note 4 if the share price approaches the conversion trigger in Note 11, any movement in revenue mix under Note 3, and the cash-concentration disclosure under Note 5 for any change in counterparty mix or credit posture.